LitCovid-sentences  

PMC:7170415 / 22790-27330 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T159 0-44 Sentence denotes Unmet Needs and the Diagnostic Test Pipeline
T160 46-85 Sentence denotes Scaling Up Access to Diagnostic Testing
T161 86-250 Sentence denotes In the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures.
T162 251-478 Sentence denotes Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61).
T163 479-648 Sentence denotes University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens.
T164 649-783 Sentence denotes Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34).
T165 784-942 Sentence denotes National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.
T166 943-1111 Sentence denotes Safely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection.
T167 1112-1342 Sentence denotes Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62).
T168 1343-1430 Sentence denotes Telemedicine combined with at-home nasal swab self-testing also has been proposed (63).
T169 1431-1622 Sentence denotes Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients.
T170 1623-1800 Sentence denotes Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts.
T171 1802-1879 Sentence denotes Alternatives to Usual Specimen Types, Collection Devices, and Transport Media
T172 1880-1953 Sentence denotes Nasopharyngeal swabs are the recommended specimen for molecular analysis.
T173 1954-2131 Sentence denotes The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products.
T174 2132-2284 Sentence denotes As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31).
T175 2285-2464 Sentence denotes Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48).
T176 2465-2732 Sentence denotes The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65).
T177 2733-2872 Sentence denotes The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34).
T178 2873-2964 Sentence denotes The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear.
T179 2966-3015 Sentence denotes Diagnostics Pipeline in the Short and Medium Term
T180 3016-3352 Sentence denotes Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as for the accurate determination of live viral shedding among patients in the convalescence phase to inform de-isolation decisions (Figure 2).
T181 3353-3473 Sentence denotes Further, it is critical to advance solutions that require less well-equipped laboratories to curb the pandemic globally.
T182 3474-3707 Sentence denotes The Foundation for Innovative New Diagnostics (FIND) and others have created online resources to collate the rapidly evolving set of assays at various stages of development, from proof of concept to full regulatory approval (20, 53).
T183 3708-3917 Sentence denotes Simple antigen-based tests, if sensitive enough, might be useful in lower-resource and home settings to inform quarantine and spatial distancing measures for patients without severe illness and their contacts.
T184 3918-4247 Sentence denotes Novel technologies, such as Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)-based diagnostics are being used to develop rapid, simple, low-cost, portable, temperature-stable assays for deployment in the field in nontraditional and resource-limited settings, such as airports and border crossings (20, 51, 54).
T185 4248-4340 Sentence denotes Other technologies might be deployed to lower-resource settings if they can be standardized.
T186 4341-4540 Sentence denotes For example, it might be possible to leverage existing loop-mediated isothermal amplification testing networks established for other diseases, such as human African trypanosomiasis surveillance (66).